A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C/C DNA sequence in the 5-HT.sub.2A receptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.

 
Web www.patentalert.com

< Lactams as tachykinin antagonists

< Monopolar and bipolar current application for transdermal drug delivery and analyte extraction

> Combination therapy for treatment of refractory depression

> Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
~ 00280